Special Issue

Advances in Cell Therapy of Neurodegenerative Diseases

Message from the Guest Editor

Neurodegenerative diseases are caused by progressive loss of structure and/or function of neurons. The lack of efficient therapies for neurodegenerative disorders leads to a significant burden on society and a high economic impact. Over the past 20 years, stem cell therapy has emerged as a promising strategy for treating neurodegenerative diseases. This Special Issue of *Brain Sciences* aims to present a collection of studies detailing the most recent progress of stem cell treatments in neurodegenerative diseases. Authors are invited to submit research articles including experimental and clinical studies and reviews that address a broad range of topics related to cell therapy in neurodegenerative disorders.

Guest Editor

Dr. Maryam Ghasemi-Kasman

Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol 47176-47754, Iran

Deadline for manuscript submissions

closed (15 July 2024)



Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.6
Indexed in PubMed



mdpi.com/si/161107

Brain Sciences
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
brainsci@mdpi.com

mdpi.com/journal/ brainsci





Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 5.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

